Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial
Authors:
- Rowan T. ChlebowskiRCRowan T. Chlebowski
- Garnet L. AndersonGAGarnet L. Anderson
- JoAnn E. MansonJMJoAnn E. Manson
- Ann G. SchwartzASAnn G. Schwartz
- Heather WakeleeHWHeather Wakelee
- Margery GassMGMargery Gass
- Rebecca J. RodaboughRRRebecca J. Rodabough
- Karen C. JohnsonKJKaren C. Johnson
- Jean Wactawski-WendeJWJean Wactawski-Wende
- Jane Morley KotchenJKJane Morley Kotchen
- Judith K. OckeneJOJudith K. Ockene
- Mary Jo O'SUllivanMOMary Jo O'SUllivan
Open Access
- 22 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 102 (18) , 1413-1421
Abstract
In the Women's Health Initiative (WHI) randomized controlled trial, use of estrogen plus progestin increased lung cancer mortality. We conducted post hoc analyses in the WHI trial evaluating estrogen alone to determine whether use of conjugated equine estrogen without progestin had a similar adverse influence on lung cancer. The WHI study is a randomized, double-blind, placebo-controlled trial conducted in 40 centers in the United States. A total of 10 739 postmenopausal women aged 50–79 years who had a previous hysterectomy were randomly assigned to receive a once-daily 0.625-mg tablet of conjugated equine estrogen (n = 5310) or matching placebo (n = 5429). Incidence and mortality rates for all lung cancers, small cell lung cancers, and non–small cell lung cancers in the two randomization groups were compared by use of hazard ratios (HRs) and 95% confidence intervals (CIs) that were estimated from Cox proportional hazards regression analyses. Analyses were by intention to treat, and all statistical tests were two-sided. After a mean of 7.9 years (standard deviation = 1.8 years) of follow-up, 61 women in the hormone therapy group were diagnosed with lung cancer compared with 54 in the placebo group (incidence of lung cancer per year = 0.15% vs 0.13%, respectively; HR of incidence = 1.17, 95% CI = 0.81 to 1.69, P = .39). Non–small cell lung cancers were of comparable number, stage, and grade in both groups. Deaths from lung cancer did not differ between the two groups (34 vs 33 deaths in estrogen and placebo groups, respectively; HR of death = 1.07, 95% CI = 0.66 to 1.72, P = .79). Unlike use of estrogen plus progestin, which increased deaths from lung cancer, use of conjugated equine estrogen alone did not increase incidence or death from lung cancer.Keywords
This publication has 51 references indexed in Scilit:
- Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle StudyJournal of Clinical Oncology, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004International Journal of Cancer, 2009
- Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural populationCancer, 2009
- Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical TrialCancer Epidemiology, Biomarkers & Prevention, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung CancerJournal of Clinical Oncology, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002